ClinicalTrials.gg
Active, not recruitingNCT07485283DAN-ZOSTERUpdated Oct 14, 2026

Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia

A Phase 4 interventional study of Recombinant Herpes Zoster Vaccine (Shingrix) in Cardiovascular Disease and Dementia, sponsored by Tor Biering-Sørensen. Active, not recruiting at 2 sites in Denmark. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Tor Biering-Sørensen · Phase 4, Interventional, and Prevention

How we know

Updated Oct 14, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
168,460
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults. Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes more common with increasing age. Some observational studies have suggested that vaccination against herpes zoster may also lower the risk of heart attacks, strokes, and dementia, but this has not been confirmed in randomized clinical trials.

In this study, approximately 162,000 adults aged 65 years or older living in Denmark will be randomly assigned to either receive the recombinant herpes zoster vaccine (Shingrix®) or receive no vaccine. Participants in the vaccine group will receive two doses given 2-6 months apart.

Participants will be identified and invited using Danish national registries and digital mail systems. Information about health outcomes will be collected through nationwide health registries during follow-up.

The main outcomes of the study are major cardiovascular events (heart attack, stroke, or cardiovascular death) and new diagnoses of dementia. The goal of the study is to determine whether herpes zoster vaccination can help prevent these conditions in older adults.

Read the detailed description

Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes increasingly common with age. In addition to causing acute illness and postherpetic neuralgia, observational studies have suggested that herpes zoster infection may be associated with an increased risk of cardiovascular events and dementia. Some observational studies have also reported lower risks of these outcomes among individuals vaccinated against herpes zoster. However, these findings may be affected by confounding, and randomized evidence is currently lacking.

The DAN-ZOSTER trial is a nationwide pragmatic randomized clinical trial designed to evaluate whether vaccination with the recombinant herpes zoster vaccine (Shingrix®) reduces the risk of major adverse cardiovascular events (MACE) and incident dementia in older adults.

In this open-label trial, approximately 162,000 adults aged 65 years or older will be randomized in a 1:1 ratio to receive the recombinant herpes zoster vaccine or no intervention. Participants randomized to the intervention arm will receive two intramuscular doses of Shingrix® administered 2-6 months apart. Participants randomized to the control arm will receive no study vaccination.

Outcomes and follow-up data will be obtained through linkage with Danish nationwide health registries.

The trial has two dual-primary outcomes: (1) major adverse cardiovascular events, defined as a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, and (2) incident dementia, defined as Alzheimer's disease, vascular dementia, or unspecified dementia. The study uses an event-driven design with predefined minimum follow-up requirements for each primary outcome.

02

Conditions studied

  • Cardiovascular Disease
  • Dementia

Keywords

  • herpes zoster
  • dementia
  • myocardial infarction
  • stroke
  • cardiovascular death
  • pragmatic
  • registry
  • vaccination
  • herpes zoster vaccine
  • shingles
  • randomized trial
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 168,460 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 65 years and above at the time of consent
  2. Self-reported ability to understand written and spoken Danish or English
  3. form has been signed and dated

Exclusion criteria

Exclusion Criteria:

The study has the following exclusion criteria which will be assessed through self-reporting:

  1. A prior diagnosis of dementia
  2. Chronic inflammatory rheumatic disease and concomitant therapy
  3. Prior herpes zoster vaccination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168,460 participants (actual)

Study arms

  • Experimental
    Recombinant Herpes Zoster Vaccine (Shingrix).

    Biological: Recombinant Herpes Zoster Vaccine (Shingrix)

  • No intervention
    No Herpes Zoster vaccine (control)

    Control arm, no intervention.

Interventions

  • BiologicalShingrixStudies of ShingrixShingrix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two doses of Shingrix vaccine spaced 2-6 months apart.

06

What researchers measure

Primary outcomes

  1. Hospitalization for MACE

    Defined as a composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death

    Time frame: From the first of the two initially booked study visits up to approximately 1 year

  2. New dementia

    Defined as a composite of Alzheimer's dementia, vascular dementia and unspecified dementia

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

Secondary outcomes

  1. Hospitalization for non-fatal acute coronary syndrome, non-fatal stroke, or cardiovascular death

    Defined as a composite of acute coronary syndrome, stroke and cardiovascular death Any I-diagnosis as cause of death

    Time frame: From the first of the two initially booked study visits up to approximately 1 year

  2. Hospitalization for any cardiovascular disease

    Time frame: From the first of the two initially booked study visits up to approximately 1 year

  3. Hospitalization for stroke

    Time frame: From the first of the two initially booked study visits up to approximately 1 year

  4. Hospitalization for myocardial infarction

    Time frame: From the first of the two initially booked study visits up to approximately 1 year

  5. Cardiovascular death

    Time frame: From the first of the two initially booked study visits up to approximately 1 year

  6. Inpatient and/or outpatient diagnosis of Alzheimer's dementia

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  7. Inpatient and/or outpatient diagnosis of vascular dementia

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  8. Inpatient and/or outpatient diagnosis of unspecified dementia

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

Other outcomes

  1. Hospitalization for unstable angina

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  2. Acute and/or elective coronary revascularization

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  3. Hospitalization for heart failure

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  4. Hospitalization for pulmonary embolism

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  5. Hospitalization for deep venous thrombosis

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  6. Combined endpoint of deep venous thrombosis and hospitalization for pulmonary embolism

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  7. Hospitalization for a combined end point of acute coronary syndrome, stroke, heart failure and cardiovascular death

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  8. New heart failure

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  9. Hospitalization for ischemic stroke

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  10. Hospitalization for hemorrhagic stroke

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  11. Transient ischemic attack

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  12. Hospitalization for atrial fibrillation

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  13. New atrial fibrillation

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  14. Hospitalization for pericarditis

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  15. Hospitalization for myocarditis

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  16. Hospitalization for endocarditis

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  17. Hospitalization for cardiovascular causes

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  18. All-cause hospitalization

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  19. All-cause death

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  20. Inpatient and/or outpatient diagnosis of new dementia or cognitive impairment

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  21. Inpatient and/or outpatient diagnosis of frontotemporal dementia

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  22. Hospitalization with delirium

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  23. Hospitalization for Herpes Zoster

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  24. Hospitalization for influenza

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  25. Laboratory-confirmed influenza infection

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

  26. Hospitalization for an infectious disease

    Time frame: From the first of the two initially booked study visits up to approximately 3 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — In this trial, baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2029, 38 months after the start.

Of 107 non-industry phase 4 interventional studies under Cardiovascular Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 76. This study's planned 38 months is below that.

Counting every sponsor, half of 113 studies reached it within 46 months; a quarter within 26 and three quarters within 64.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2029 → Jun 2029 and completion Apr 2029 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 20, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Jun 2029was Apr 2029
CompletionEst.
Jun 2029was Apr 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Primary completion
Apr 2029→Jun 2029
Oct 14, 2026
Study completion
Apr 2029→Jun 2029
Oct 14, 2026
Enrollment
162000 (estimated)→168460 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Active, not recruiting
    Primary completion Apr 2029→Jun 2029
    Study completion Apr 2029→Jun 2029
    Enrollment 162000 (estimated)→168460 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07485283
Lead sponsor
Tor Biering-Sørensen
Collaborators
GlaxoSmithKline
Responsible party
Tor Biering-Sørensen (Professor, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Mar 20, 2026
Start date
Apr 28, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Tor Biering-Sørensen, MD, PhD, MSc, MPH
study chair · Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion